Johannes Lengler

Title: **Johannes Lengler: Innovator in Gene Therapy**

Introduction

Johannes Lengler, an accomplished inventor based in Vienna, Austria, has made significant strides in the field of medical innovation. With a remarkable portfolio of six patents, Lengler is at the forefront of developing advanced gene therapies aimed at treating hemophilia. His contributions showcase a blend of ingenuity and dedication to improving patient outcomes.

Latest Patents

One of Johannes Lengler's latest patents focuses on the gene therapy of hemophilia B using viral vectors that encode recombinant Factor IX variants with enhanced expression. This disclosure presents codon-altered polynucleotides designed for optimal expression in mammalian cells. Moreover, the patent provides methods for dosing a hemophilia B patient with these polynucleotide constructs, which are critical for effective treatment.

Additionally, he has developed viral vectors targeting hemophilia A, featuring codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian systems. This innovative approach holds promise for improving gene therapy techniques, making it an important step forward in the treatment of hemophilia A.

Career Highlights

Throughout his career, Johannes has worked diligently at notable organizations, including Baxalta GmbH and Takeda Pharmaceutical Company Limited. His roles at these companies have equipped him with valuable expertise and insights into the pharmaceutical industry, allowing him to drive innovations that address pressing medical challenges.

Collaborations

Collaboration has been a significant aspect of Johannes Lengler's journey as an inventor. He has closely worked with professionals such as Franziska Horling and Hanspeter Rottensteiner, contributing to a dynamic environment where innovative ideas flourish. These partnerships underline the importance of teamwork in advancing medical research and development.

Conclusion

Johannes Lengler stands out as a visionary inventor whose work in gene therapy is set to transform the landscape of hemophilia treatment. With his patented innovations and collaborations with esteemed colleagues, he continues to push the boundaries of what is possible in medical science, promising a brighter future for patients affected by these conditions.